Form 4: Tenaya Therapeutics Director Receives Stock Option Grant

Director June Lee was granted 120,000 stock options in Tenaya Therapeutics, Inc. as part of the company's equity incentive plan.

Summary

• Director June Lee received a grant of 120,000 stock options on May 28, 2026.
• The options have an exercise price of $0.7989 per share.
• The grant is subject to a vesting schedule with full vesting occurring on May 28, 2027, or the day before the next annual stockholders meeting, whichever is earlier.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a routine administrative disclosure regarding director compensation that does not signal a change in company strategy or financial health.

Positives

• Alignment of director interests with long-term shareholder value through equity-based compensation.

Negatives

• Potential for future shareholder dilution upon the exercise of these options.

Risks

• Market volatility affecting the value of the underlying common stock.
• Dependence on continued service as a director to satisfy vesting requirements.

Future Outlook

The options vest in full on May 28, 2027, or the day before the next annual meeting of stockholders, contingent upon continued service.

Management Comments

• The grant was issued pursuant to the Amended and Restated Tenaya Therapeutics, Inc. 2021 Equity Incentive Plan.

Industry Context

StockSavvy.ai notes that equity grants to non-employee directors are standard practice in the biotechnology sector to attract and retain board talent while aligning incentives with long-term clinical and commercial milestones.

Comparison to Industry Standards

• The use of equity incentive plans for director compensation is consistent with standard corporate governance practices for mid-cap and small-cap biotech firms.
• The vesting period of one year is typical for annual director equity grants in the industry.

Stakeholder Impact

• Shareholders may experience minor dilution if these options are exercised in the future.

Next Steps

• Vesting of options on May 28, 2027.

Key Dates

Keywords

Tenaya Therapeutics, TNYA, Form 4, Insider Trading, Stock Options, Equity Incentive Plan